Cargando…

A genome-wide single-cell 3D genome atlas of lung cancer progression

Alterations in three-dimensional (3D) genome structures are associated with cancer(1–5). However, how genome folding evolves and diversifies during subclonal cancer progression in the native tissue environment remains unknown. Here, we leveraged a genome-wide chromatin tracing technology to directly...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Miao, Jin, Shengyan, Agabiti, Sherry S., Jensen, Tyler B., Yang, Tianqi, Radda, Jonathan S. D., Ruiz, Christian F., Baldissera, Gabriel, Muzumdar, Mandar Deepak, Wang, Siyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10401964/
https://www.ncbi.nlm.nih.gov/pubmed/37546882
http://dx.doi.org/10.1101/2023.07.23.550157
Descripción
Sumario:Alterations in three-dimensional (3D) genome structures are associated with cancer(1–5). However, how genome folding evolves and diversifies during subclonal cancer progression in the native tissue environment remains unknown. Here, we leveraged a genome-wide chromatin tracing technology to directly visualize 3D genome folding in situ in a faithful Kras-driven mouse model of lung adenocarcinoma (LUAD)(6), generating the first single-cell 3D genome atlas of any cancer. We discovered stereotypical 3D genome alterations during cancer development, including a striking structural bottleneck in preinvasive adenomas prior to progression to LUAD, indicating a stringent selection on the 3D genome early in cancer progression. We further showed that the 3D genome precisely encodes cancer states in single cells, despite considerable cell-to-cell heterogeneity. Finally, evolutionary changes in 3D genome compartmentalization – partially regulated by polycomb group protein Rnf2 through its ubiquitin ligase-independent activity – reveal novel genetic drivers and suppressors of LUAD progression. Our results demonstrate the importance of mapping the single-cell cancer 3D genome and the potential to identify new diagnostic and therapeutic biomarkers from 3D genomic architectures.